公开(公告)号：US08518466B2

公开(公告)日：2013-08-27

申请号：US12451544

申请日：2008-09-27

申请人： Changming Chen ,  Yanshen Wen ,  Danyang Li ,  Pengju Mao ,  Yihua Peng

发明人： Changming Chen ,  Yanshen Wen ,  Danyang Li ,  Pengju Mao ,  Yihua Peng

IPC分类号： C01G3/05

CPC分类号： C01B19/007 ,  A23K20/24 ,  A23K20/30 ,  A23V2002/00 ,  C01B19/02 ,  C01G3/00 ,  C01G3/05 ,  C01G3/10 ,  C01P2004/61 ,  C01P2004/84 ,  A23V2250/1626 ,  A23V2250/1588

摘要： A preparation method for selenium covered basic copper chloride includes the steps of: (a) adding crystalline basic copper chloride (TBCC), water and stabilizer in a reactor; adding sodium hydroxide solution with stirring; reacting to form a hydroxyl-modified crystalline basic copper chloride after discharge, washing, and negative pressure leaching; (b) adding the hydroxyl-modified crystalline basic copper chloride and water in the reactor, adding selenous acid with stirring; adding copper sulfate pentahydrate after reaction; forming selenium covered basic copper chloride comprising crystalline basic copper chloride, basic cuprous selenide, and basic cupric sulfate after discharge, rinsing, negative pressure filtration, and drying. The selenium covered basic copper chloride is used as feed addictives of trace elements having nonhygroscopic property, good liquidity, and stable chemical property. The selenium covered basic copper chloride is easy to incorporate with feed, low price, low cost in adding, weak acidic solubility, easy to absorb.

摘要翻译： 硒覆盖的碱性氯化铜的制备方法包括以下步骤：（a）在反应器中加入结晶碱性氯化铜（TBCC），水和稳定剂; 搅拌加入氢氧化钠溶液; 在排出，洗涤和负压浸出后反应形成羟基改性的结晶碱性氯化铜; （b）在反应器中加入羟基改性的结晶碱性氯化铜和水，搅拌加入硒酸; 反应后加入五水硫酸铜; 形成硒覆盖碱性氯化铜，包括结晶碱性氯化铜，碱式亚铜化亚铜和碱性硫酸铜，放电后，冲洗，负压过滤和干燥。 硒覆盖的碱性氯化铜用作具有不吸湿性，流动性好，化学性能稳定的微量元素的添加剂。 硒覆盖碱性氯化铜容易掺入饲料，价格低廉，成本低廉，酸性溶解性弱，易吸收。

公开(公告)号：US20100029643A1

公开(公告)日：2010-02-04

申请号：US12514247

申请日：2007-11-08

申请人： Gurmit Grewal ,  Edward Hennessy ,  Victor Kamhi ,  Danyang Li ,  Paul Lyne ,  Vibha Oza ,  Jamal Carlos Saeh ,  Qibin Su ,  Bin Yang

发明人： Gurmit Grewal ,  Edward Hennessy ,  Victor Kamhi ,  Danyang Li ,  Paul Lyne ,  Vibha Oza ,  Jamal Carlos Saeh ,  Qibin Su ,  Bin Yang

IPC分类号： A61K31/4184 ,  C07D235/14 ,  C07D401/06 ,  C07D471/04 ,  C07D403/12 ,  C07D413/12 ,  C07D401/12 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/538 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D235/14 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/40 ,  C07D487/04 ,  C07D491/056

摘要： The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.

摘要翻译： 本发明涉及具有Edg-1拮抗活性的式（I），（Ia）和（Ib）化合物或其药学上可接受的盐，因此可用于其抗癌活性，因此可用于治疗 人或动物体。 本发明还涉及制备所述化合物的方法，含有它们的药物组合物及其在制造用于在温血动物如人中产生抗癌作用的药物中的用途。

公开(公告)号：US20090111860A1

公开(公告)日：2009-04-30

申请号：US12297791

申请日：2007-04-20

申请人： Gurmit Grewal ,  Edward Hennessy ,  Victor Kamhi ,  Danyang Li ,  Vibha Oza ,  Jamal Carlos Saeh ,  Qibin Su

发明人： Gurmit Grewal ,  Edward Hennessy ,  Victor Kamhi ,  Danyang Li ,  Vibha Oza ,  Jamal Carlos Saeh ,  Qibin Su

IPC分类号： A61K31/425 ,  C07D275/02 ,  A61P35/00 ,  C07D231/12 ,  C07D261/08 ,  A61K31/42 ,  A61K31/415

CPC分类号： C07D231/12 ,  C07D231/20 ,  C07D231/38 ,  C07D261/08 ,  C07D261/10 ,  C07D261/12 ,  C07D275/02 ,  C07D275/03

摘要： The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5bl, and also that exhibit appropriate selectivity profile(s) against other integrins.

摘要翻译： 本发明涉及介导Edg的化合物，其包括Edg-1，其制备方法，含有它们作为活性成分的药物组合物，其用作药物及其在制备药物中的用途 在具有显着血管形成或炎性成分如肿瘤相关疾病的疾病的人类的温血动物中进行治疗。 本发明还涉及抑制bbl的化合物，并且还表现出对其他整联蛋白的适当选择性分布。